Nrf2 Activation With CDDO-Methyl Promotes Beneficial and Deleterious Clinical Effects in Transgenic Mice With Sickle Cell Anemia

Activation of Nrf2, a major transcription factor that drives the antioxidant defense system, is an emerging therapeutic strategy in Sickle Cell Disease (SCD). In this study, transgenic Sickle Cell Anemia mice (SS mice) treated with CDDO-Methyl (CDDO-Me), a potent Nrf2 activator, showed reduced progression of hemolytic anemia with aging, but surprisingly also showed reduced endothelial function. Pulmonary vessels isolated from SS mice treated for 4 months with CDDO-Me displayed a diminished response to nitric oxide (NO)-induced vasodilation compared to littermates given vehicle. It is unclear what molecular mechanism underly the vascular impairment, however, our in vitro assays revealed that CDDO-Me induced the expression of the endothelin receptor (ETA and ETB) in vascular smooth muscle cells. Endothelin signaling is associated with increased vascular tone and vasoconstriction. This study underscores the importance of pre-clinical benefit-risk investigations of Nrf2 activating compounds which may be used to treat patients with SCD.

[1]  D. Grimm,et al.  Endothelin Receptor Antagonists: Status Quo and Future Perspectives for Targeted Therapy , 2020, Journal of clinical medicine.

[2]  Keleku-Lukwete N, Suzuki M, Panda H, et al. Nrf2 activation in myeloid cells and endothelial cells differentially mitigates sickle cell disease pathology in mice. Blood Adv. 2019;3(8):1285-1297. , 2019, Blood Advances.

[3]  Masayuki Yamamoto,et al.  Nrf2 activation in myeloid cells and endothelial cells differentially mitigates sickle cell disease pathology in mice. , 2019, Blood advances.

[4]  Heidi Hynynen,et al.  Nitro-Oleic Acid Regulates Endothelin Signaling in Human Endothelial Cells , 2017, Molecular Pharmacology.

[5]  R. Linker,et al.  Dimethyl fumarate in multiple sclerosis: latest developments, evidence and place in therapy , 2016, Therapeutic advances in chronic disease.

[6]  A. Ashley-Koch,et al.  Phase 1 Study of a Sulforaphane-Containing Broccoli Sprout Homogenate for Sickle Cell Disease , 2016, PloS one.

[7]  S. Ofori-Acquah,et al.  Nonhematopoietic Nrf2 dominantly impedes adult progression of sickle cell anemia in mice. , 2016, JCI insight.

[8]  J. D. Engel,et al.  Amelioration of inflammation and tissue damage in sickle cell model mice by Nrf2 activation , 2015, Proceedings of the National Academy of Sciences.

[9]  M. Sporn,et al.  Dimethyl fumarate and the oleanane triterpenoids, CDDO-imidazolide and CDDO-methyl ester, both activate the Nrf2 pathway but have opposite effects in the A/J model of lung carcinogenesis. , 2015, Carcinogenesis.

[10]  R. Bomprezzi.  Dimethyl fumarate in the treatment of relapsing–remitting multiple sclerosis: an overview , 2015, Therapeutic advances in neurological disorders.

[11]  Shufeng Zhou,et al.  Bardoxolone methyl (CDDO-Me) as a therapeutic agent: an update on its pharmacokinetic and pharmacodynamic properties , 2014, Drug design, development and therapy.

[12]  G. Bakris,et al.  Mechanisms Contributing to Adverse Cardiovascular Events in Patients with Type 2 Diabetes Mellitus and Stage 4 Chronic Kidney Disease Treated with Bardoxolone Methyl , 2014, American Journal of Nephrology.

[13]  R. Gold,et al.  Dimethyl Fumarate for Treatment of Multiple Sclerosis: Mechanism of Action, Effectiveness, and Side Effects , 2013, Current Neurology and Neuroscience Reports.

[14]  M. Konopleva,et al.  A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas , 2012, Clinical Cancer Research.

[15]  M. Gladwin,et al.  Hemolysis and cell-free hemoglobin drive an intrinsic mechanism for human disease. , 2012, The Journal of clinical investigation.

[16]  Philip Raskin,et al.  Bardoxolone methyl and kidney function in CKD with type 2 diabetes. , 2011, The New England journal of medicine.

[17]  D. Warnock,et al.  Effect of Bardoxolone Methyl on Kidney Function in Patients with T2D and Stage 3b–4 CKD , 2011, American Journal of Nephrology.

[18]  H. Meiselman,et al.  A novel human gamma-globin gene vector for genetic correction of sickle cell anemia in a humanized sickle mouse model: critical determinants for successful correction. , 2009, Blood.

[19]  I. Preston,et al.  Optimizing endothelin receptor antagonist use in the management of pulmonary arterial hypertension , 2008, Vascular health and risk management.

[20]  T. Townes,et al.  Correction of sickle cell disease by homologous recombination in embryonic stem cells. , 2006, Blood.

[21]  D. Granger,et al.  Critical role of endothelial cell-derived nitric oxide synthase in sickle cell disease-induced microvascular dysfunction. , 2006, Free radical biology & medicine.

[22]  DelindaA . Johnson,et al.  Nrf2, a multi‐organ protector? , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[23]  H. Billett,et al.  The older sickle cell patient , 2004, American journal of hematology.

[24]  S. Biswal,et al.  Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray. , 2002, Cancer research.

[25]  S. Thein,et al.  Sickle cell disease in the older adult. , 2017, Pathology.

[26]  S. Ofori-Acquah,et al.  Inflammatory targets of therapy in sickle cell disease. , 2016, Translational research : the journal of laboratory and clinical medicine.